BRAF Inhibitor Resistance Mechanism I Pharmaron CRO

Poster Authors:

Qiuyuan Yang¹, Kaiqiang Hu¹, Lei Liu^2, Tingting Guo², Haiyan Gu², Pengwei Pan¹, Fang He¹

This poster was presented at AACR 2024.

Methods Applied to Investigate Dabrafenib’s Resistance Mechanism

This research focuses on understanding the resistance mechanism for BRAF inhibitor Dabrafenib, by investigating the varying efficacy across cancer types. A comprehensive drug resistance mechanism analysis for Dabrafenib through screening of hundreds of cell lines using a the Cell Titer-Glo (CTG) assay. This approach measured Dabrafenib’s potency, successfully distinguishing resistant and sensitive cell types. Publicly available high-throughput sequencing data was then analyzed by our bioinformaticians to correlate gene expression profiles with Dabrafenib sensitivity. Finally, synergistic drug testing validated the identified resistance mechanism.

Key Findings on BRAF Inhibitor Resistance Mechanism Research

Dabrafenib was highly effective in skin cancer cell lines but demonstrated resistance in myeloid cancer cell lines.
Resistance strongly correlated with the upregulation of the PI3K signaling pathway.
Analysis of clinical datasets together with in vitro experiments identified elevated PIK3CG levels are key contributors to drug resistance.
Combination testing of PI3K inhibitors and Dabrafenib successfully reduced resistance, presenting a promising strategy for overcoming drug resistance.

Capabilities

Knowledge Center

Cancer Cell Panel Screening for Oncology Drug Discovery

Cell Biology

Bioinformatics

Connect with a Scientific Expert

Complete the form to access resource

Name(Required)

First Last

Company Name(Required)

Job Title(Required)

Country(Required)

State(Required)

Message

Email(Required)

Lead Source(Required)

By completing and submitting this form, you acknowledge that you have read and understood our Privacy Policy, and you consent to the collection and processing of your personal data by Pharmaron for the purpose of responding to your inquiry. You also agree to be contacted by Pharmaron regarding relevant services and updates. You may withdraw your consent at any time.

Pharmaron’s Approach to Identify Cancer Drug Resistance Mechanisms

At Pharmaron, we address the challenges of uncovering drug resistance mechanisms through a blend of disciplines including bioinformatics, proteomics, genomics, and cell screening. We provide the expertise and technology to accelerate discoveries. We help our clients to identify resistance mechanisms effectively and pave the way for innovative therapies to overcome cancer drug resistance mechanisms.

Access the full case study by downloading the poster.